Gilead Sciences has agreed to acquire PepStar Therapeutics’ oral inflammation drug program for $1.275 billion, strengthening its efforts to develop treatments for inflammatory bowel disease (IBD). The Gilead and PepStar inflammation drug deal will give Gilead worldwide rights to the program, which is expected to close in the fourth quarter of 2026.
In this agreement, Gilead will acquire PepStar’s oral interleukin-23 receptor (IL-23R) inhibitor program, including its lead candidate, HCXT-2001. The drug remains in early-stage clinical testing and has not been approved for use.
The Gilead and PepStar inflammation drug deal marks another step in Gilead’s strategy to expand beyond its established HIV business and build its presence in immune-mediated diseases.
What Is PepStar’s Experimental Inflammation Drug HCXT-2001?
HCXT-2001 is an investigational and experimental medicine designed to block a key immune-system pathway involved in inflammation. It includes a macrocyclic peptide inhibitor of IL-23R.
IL-23R is a receptor involved in immune signaling. By blocking this receptor, HCXT-2001 aims to interfere with inflammatory processes that contribute to immune-mediated diseases.
According to Gilead’s announcement, HCXT-2001 has an extended half-life, meaning it may remain in the body for a longer period. The company sees potential for the drug to be developed as a standalone treatment or in combination with other medicines in its pipeline.
Gilead identifies inflammatory bowel disease as a key area of interest for the candidate, while psoriasis represents another potential application of IL-23 pathway research.
What Do HCXT-2001 Drug’s Clinical Trial Results Say?
Despite the Gilead and PepStar inflammation drug deal, HCXT-2001 remains in Phase 1 clinical trials. The candidate had no published clinical data at the time of the announcement. Gilead has also stated that the inflammation drug’s safety and effectiveness have not been established and that no regulatory authority has approved it.
Further studies must determine whether HCXT-2001 can safely deliver meaningful benefits to patients. The PepStar inflammation drug program acquisition therefore gives Gilead a development opportunity rather than an established treatment.
How Does the Purchase Strengthen Gilead’s Inflammatory Disease Pipeline?
The Gilead and PepStar inflammation drug deal comes shortly after Gilead reported positive mid-stage results for emvistegrast, its separate investigational medicine for ulcerative colitis, a form of inflammatory bowel disease. Gilead plans to advance emvistegrast toward Phase 3 testing.
The two candidates target different biological pathways. HCXT-2001 targets IL-23R, while emvistegrast targets the α4β7 integrin pathway, which plays a role in immune-cell movement into the gut.
Gilead sees potential to develop HCXT-2001 alone or alongside emvistegrast as a daily oral treatment approach for people living with IBD.
“HCXT-2001 adds a potentially differentiated oral approach to our growing inflammation pipeline,” said Dietmar Berger, Gilead’s chief medical officer, in the company’s announcement.
The strategy could give Gilead more options for developing treatments that address inflammation through complementary mechanisms. However, the benefits of combining HCXT-2001 and emvistegrast have not yet been established.
What Happens Next in PepStar Inflammation Drug Program Acquisition?
Inflammatory bowel disease includes chronic conditions such as Crohn’s disease and ulcerative colitis. These disorders involve persistent inflammation in the digestive tract and can require long-term treatment. An oral medicine for IBD could offer a useful alternative for some patients if future trials demonstrate safety and effectiveness.
The Gilead and PepStar inflammation drug deal is expected to close in the fourth quarter of 2026, pending customary conditions. After closing, further clinical development will determine whether HCXT-2001 can progress toward later-stage trials and potential regulatory review.
